Drug Trial Radar · NCT01808092
A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia
Last checked: Nov 19, 2026Latest source record: Sep 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
969
Actual
Start
Apr 2013
Primary completion
Jan 2016
Study completion Jan 2016
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 11, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the effects of Ceftazidime-Avibactam compared to Meropenem for treating hospitalized adults with nosocomial pneumonia including ventilator-associated pneumonia
Conditions
- Nosocomial Pneumonia (NP)
- Ventilator-associated Pneumonia (VAP)
Interventions
ceftazidim-avibactam (CAZ-AVI, experimental product)Drug
2000mg ceftazidime plus 500mg avibactam
meropenem (active comparator)Drug
1000mg of Meropenem
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Modified Intent-to-treat Analysis Set (Co-primary Analyses)Time frame: At the test-of-cure (TOC) visit (Day 21 to 25)
- The Number of Patients With Clinical Cure at Test-of-cure (TOC) Visit in the Clinically Evaluable at TOC Analysis Set (Co-primary Analyses)Time frame: At the test-of-cure (TOC) visit (Day 21 to 25)
Locations
123 sites in 26 countries. Site status is shown where the registry gives one.
Research Site
Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
Florida, Argentina
Research Site
La Plata, Argentina
Research Site
Mendoza, Argentina
Research Site
Belo Horizonte, Brazil
Research Site
Campinas/SP, Brazil
Research Site
Curitiba, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
Burgas, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Rousse, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Beijing, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Guangzhou, China
Research Site
Haikou, China
Research Site
Hangzhou, China
Research Site
Jiangyin, China
Research Site
Nanchang, China
Research Site
Qingdao, China
Research Site
Sanya, China
Research Site
Shanghai, China
Research Site
Shenyang, China
Research Site
Shenzhen, China
Research Site
Suzhou, China
Research Site
Tianjin, China
Research Site
Xi'an, China
Research Site
Xiamen, China
Research Site
Yangzhou, China
Research Site
Zhanjiang, China
Research Site
Kolín, Czechia
Research Site
Kyjov, Czechia
Research Site
Praha 10, Prague, Czechia
Research Site
Limoges, France
Research Site
Nantes, France
Research Site
Paris, France
Research Site
Pierre-Bénite, France
Showing 40 of 123 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.